Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Inclusion Criteria: * Adult and adolescent (12-65 years old) allergic rhinitis patients should meet each of the following criteria: * Adult with age of 18-65 years for allergic rhinitis with or without allergic asthma. Adolescent with age of 12-17 years for allergic rhinitis. * Clinical history and a positive test of dust mite sensitization (positive skin prick test result ≥+++ or positive specific IgE test result ≥grade 3). * Persistent moderate to severe dust mite allergic rhinitis despite use of symptom-relieving medication (symptom assessment defined as to assess symptoms of rhinitis by VAS score≥ 5). * Newly prescribed with ACARIZAX®. * For adults, must provide signed informed consent; for adolescents, written informed consent must be obtained from both guardian and patient himself/herself if the level of intellectual maturity makes it appropriate. * Patients with allergic asthma should also meet both of the following criteria: * Dust mite induced asthma not well controlled by inhaled corticosteroids and associated with mild to severe dust mite allergic rhinitis. * FEV1 ≥ 70% of predicted value after adequate pharmacologic treatment. Exclusion Criteria: * Patients with hypersensitivity to any of the excipients. * Patients with severe asthma exacerbations within the last 3 months. * Asthmatic patients experiencing an acute respiratory tract infection should have the treatment postponed. * Patients with acute severe oral inflammation and oral wounds. * P…